M&A / Deals Gilead outlays $5bn to acquire ADC specialist Tubulis Pharmaceutical TechnologySixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs.M&A / DealsRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) Pharmaceutical Technology Sixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist TubulisNext: Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
